



Amgen Statement On Government Budget Analysis For Oral-Only Treatments For Dialysis Patients

February 22, 2013

THOUSAND OAKS, Calif., Feb. 22, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) notes that an analysis by the Congressional Budget Office released this week shows that, contrary to the implications of past media reports, keeping oral-only drugs in Medicare Part D would actually achieve significant savings over time for both taxpayers and the Medicare program.

As noted by the Government Accountability Office (GAO), it is important that the Centers for Medicare and Medicaid Services (CMS) take the time needed to develop quality metrics and further develop their data systems, both of which are essential to providing quality care for an elderly and chronically ill patient population.

Amgen will continue to advocate for sound federal policies that enhance access to care for these patients.

For more background, please visit Our Perspectives on www.amgen.com.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: <http://photos.prnewswire.com/prnh/20081015/AMGENLOGO>)

SOURCE Amgen